Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816150 | 0.75 | MAP4K4 (0.48) | MAP4K4PIK3CAPI4KAPI4KBRAB9A | |
| SCHEMBL10200524 | 0.73 | MAP4K4 (0.56) | MAP4K4BRD4JAK2USP7 | |
| SCHEMBL8784588 | 0.69 | MAP4K4 (0.69) | MAP4K4BRD4 | |
| SCHEMBL4018886 | 0.67 | BRD4 (0.53) | BRD4JAK2GPR55 | |
| SCHEMBL30522551 | 0.67 | BRD4 (0.53) | BRD4JAK2GPR55 | |
| SCHEMBL7944361 | 0.66 | MAP4K4 (0.55) | MAP4K4BRD4JAK2 | |
| SCHEMBL31434797 | 0.65 | OXTR (0.44) | PIK3CAPI4KAPI4KB | |
| SCHEMBL30522586 | 0.64 | PTGS2 (0.37) | MAP4K4PIK3CABRD4RAB9AGPR55 | |
| SCHEMBL15815842 | 0.64 | MAP4K4 (0.49) | MAP4K4BRD4JAK2USP7 | |
| SCHEMBL21166 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861637-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2016-05-12 | — | — | US | disclosed |
| US-9271978-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS CORP. (CA) | 2016-03-01 | — | — | US | disclosed |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | BRD4, BRDT, BRD3 | MAP4K4 1544/4885S1PR1 3021/4885PIK3CA 3286/4885 |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRDT, BRD3 | MAP4K4 1544/4885S1PR1 3021/4885PIK3CA 3286/4885 |
| US-20140179648-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | BRD4, BRDT, BRD3 | MAP4K4 1544/4885S1PR1 3021/4885PIK3CA 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.